Clinical Trials

100 enrolled

Phase 3 Not yet recruiting

Biliary Tract Neoplasms, Jaundice, Obstructive

NCT06622057 2026-04-14

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

195 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04910386 2026-03-25

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

126 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Phase 1/2 Not yet recruiting

Biliary Tract Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07169916 2025-09-12

YJ-BTC

210 enrolled

Biliary Tract Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07160283 2025-09-08

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

96 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

63 enrolled

Biliary Tract Neoplasms

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Biliary Tract Neoplasms

NCT07099794 2025-08-01

A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen

90 enrolled

Biliary Tract Neoplasms

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Biliary Tract Neoplasms

NCT06993025 2025-05-28

Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

Biliary Tract Neoplasms

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

74 enrolled

Biliary Tract Neoplasms

NCT06903273 2025-03-30

TisGCS for BTC

35 enrolled

Phase 4 Not yet recruiting

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06818773 2025-02-10

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

35 enrolled

Biliary Tract Neoplasms

NCT06654947 2024-12-16

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

23 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

206 enrolled

Biliary Tract Neoplasms

NCT06569225 2024-08-26

NEOLANGIO

40 enrolled

Biliary Tract Neoplasms

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

80 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06502080 2024-07-17

RADITOP

128 enrolled

Biliary Tract Neoplasms

NCT06389500 2024-04-29

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

NCT06375928 2024-04-19

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)

44 enrolled

Biliary Tract Neoplasms

NCT06375954 2024-04-19

EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)

96 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT06037655 2023-09-14

Modified